Fei Huang

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer
    Fei Huang
    Bristol Myers Squibb Co, Route 206 and Province Line Rd, Room E1 293, Princeton, NJ 08453, USA
    Clin Cancer Res 18:1156-66. 2012
  2. ncbi Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity
    Ayan Banerjea
    Centre for Academic Surgery, Barts and the London Queen Mary School of Medicine and Dentistry, The Royal London Hospital, Whitechapel, London, E1 1BB, UK
    Mol Cancer 3:21. 2004
  3. ncbi Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study
    Per Hall
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    BMC Med 4:16. 2006
  4. ncbi The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors
    Fei Huang
    Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Cancer Res 69:161-70. 2009
  5. ncbi Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection
    Fei Huang
    Departments of Clinical Discovery and Oncology Discovery, Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    Cancer Res 67:2226-38. 2007
  6. ncbi Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
    Xi De Wang
    Pharmaceutical Research Institute, Bristol Myers Squibb, Princeton, New Jersey, 08543, USA
    Genome Biol 8:R255. 2007
  7. ncbi Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model
    Fei Huang
    Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Cancer Res 70:7221-31. 2010
  8. ncbi Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807
    Joseph E Dinchuk
    Bristol Myers Squibb Research and Development, K23 02, Princeton, New Jersey 08543 4000, USA
    Endocrinology 151:4123-32. 2010
  9. ncbi Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    Moshe Talpaz
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, USA
    N Engl J Med 354:2531-41. 2006
  10. ncbi Optimal probing of optical contrast of breast lesions of different size located at different depths by US localization
    Quing Zhu
    Bioengineering Program, Electrical and Computer Engineering Department, University of Connecticut, 371 Fairfield Rd, Storrs, CT 06269, USA
    Technol Cancer Res Treat 5:365-80. 2006

Collaborators

Detail Information

Publications13

  1. ncbi Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer
    Fei Huang
    Bristol Myers Squibb Co, Route 206 and Province Line Rd, Room E1 293, Princeton, NJ 08453, USA
    Clin Cancer Res 18:1156-66. 2012
    ....
  2. ncbi Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity
    Ayan Banerjea
    Centre for Academic Surgery, Barts and the London Queen Mary School of Medicine and Dentistry, The Royal London Hospital, Whitechapel, London, E1 1BB, UK
    Mol Cancer 3:21. 2004
    ..We aimed to compare the gene expression profiles of MSI-H and MSS cancers to provide evidence for an activated immune response in the former...
  3. ncbi Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study
    Per Hall
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    BMC Med 4:16. 2006
    ..Postmenopausal hormone-replacement therapy (HRT) increases breast-cancer risk. The influence of HRT on the biology of the primary tumor, however, is not well understood...
  4. ncbi The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors
    Fei Huang
    Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Cancer Res 69:161-70. 2009
    ..Further exploration of mechanisms for intrinsic and acquired drug resistance by these preclinical studies may lead to more rationally designed drugs that target multiple pathways for enhanced antitumor efficacy...
  5. ncbi Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection
    Fei Huang
    Departments of Clinical Discovery and Oncology Discovery, Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    Cancer Res 67:2226-38. 2007
    ..Our results implicate that dasatinib may represent a valuable treatment option in this difficult-to-treat population. To test this hypothesis, clinical studies are now under way to determine the activity of dasatinib in these patients...
  6. ncbi Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
    Xi De Wang
    Pharmaceutical Research Institute, Bristol Myers Squibb, Princeton, New Jersey, 08543, USA
    Genome Biol 8:R255. 2007
    ..To aid the clinical development of dasatinib in prostate cancer, we utilized preclinical models to identify potential molecular markers for patient stratification and efficacy monitoring...
  7. ncbi Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model
    Fei Huang
    Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Cancer Res 70:7221-31. 2010
    ..It provides insights into the differential acquired resistance mechanisms for IGF-IR/IR small-molecule inhibitor versus anti-IGF-IR antibody...
  8. ncbi Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807
    Joseph E Dinchuk
    Bristol Myers Squibb Research and Development, K23 02, Princeton, New Jersey 08543 4000, USA
    Endocrinology 151:4123-32. 2010
    ....
  9. ncbi Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    Moshe Talpaz
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, USA
    N Engl J Med 354:2531-41. 2006
    ..CONCLUSIONS: Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].)...
  10. ncbi Optimal probing of optical contrast of breast lesions of different size located at different depths by US localization
    Quing Zhu
    Bioengineering Program, Electrical and Computer Engineering Department, University of Connecticut, 371 Fairfield Rd, Storrs, CT 06269, USA
    Technol Cancer Res Treat 5:365-80. 2006
    ..A clinical example of a large invasive carcinoma is presented to demonstrate the application of this novel technique...
  11. ncbi KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis
    Goutham Narla
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 118:2711-21. 2008
    ..Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target...
  12. ncbi Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
    Yudi Pawitan
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Breast Cancer Res 7:R953-64. 2005
    ..Breast cancer expression profiling has so far mainly been used to identify women with a poor prognosis as candidates for adjuvant therapy but without demonstrated value for therapy prediction...
  13. ncbi Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies
    Suzanne Egyhazi
    Clin Chem 50:975-6. 2004